Exscientia is at the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavour. Their AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.